The FDA has approved Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough) 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4-11 years of ...

Mometasone furoate 110mcg/inh, 220mcg/inh; pwd for oral inhalation; with dose counter. Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of ...

KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today that ASMANEX(R) TWISTHALER(R) 110 mcg (mometasone furoate ...

A new inhaled steroid treatment for preventing asthma attacks in young children has been approved by the Food and Drug Administration, the drugmaker Schering-Plough Corp. said. Its Asmanex Twisthaler ...

April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...

Asmanex Twisthaler has been launched by Schering-Plough as therapy in the control and management of mild, moderate or severe persistent asthma in Asmanex Twisthaler has been launched by ...

Mar. 23 -- TUESDAY, Feb. 5 (HealthDay News) -- Schering-Plough's Asmanex Twisthaler, an inhaled steroid designed to prevent asthma attacks, has been approved by the U.S. Food and Drug Administration ...

KENILWORTH, N.J. The Food and Drug Administration has approved Schering-Plough’s asthma inhaler Asmanex twisthaler 110 mcg for the maintenance of asthma as a preventive therapy in patients 4 to 11 ...

NEW YORK (MarketWatch) -- Schering-Plough Corp. lifted 27 cents, or 1.5 percent, to $27.29 in premarket trade Thursday after the U.S. Food & Drug Administration approved the Asmanex Twisthaler 220 mcg ...

In a joint statement today, Schering-Plough and Novartis announced changes to the collaboration agreements regarding both companies’ respiratory portfolios. Schering Plough will assume exclusive ...